Johnson & Johnson and AstraZeneca will just have to duke it out for share of the market for SGLT2 treatments for diabetes. A potential third competitor from Eli Lilly and Boehringer Ingelheim, empagliflozin, failed to win FDA approval, thanks to problems at a Boehringer manufacturing plant.
Danish medical device maker Coloplast is said to have paid $16 million to settle lawsuits claiming it injured women with vaginal-mesh inserts. With settlement talk swirling around at least 5 more makers of the plagued devices, that has some watchers saying the time may be ripe for a global settlement.
Drugmakers aren't spending as much on speaking fees these days. Some companies--namely Pfizer and Eli Lilly--have slashed physician payments by more than half.
The earnings reports for the biggest of Big Pharma are all in. Bayer reported last week, making it possible to see how they stacked up as they came into the new year. There are no big surprises....
Johnson & Johnson was cautiously lauded for its clinical trial data-sharing initiative, but Roche's project was pilloried. Now Novartis has joined its Swiss peer in rolling out an underwhelming transparency program.
It's Johnson & Johnson's last stand in Arkansas. The drugmaker has its chance Thursday to persuade the Arkansas Supreme Court to toss out the $1.2 billion judgment awarded in a court fight over Risperdal marketing.
Johnson & Johnson is moving ahead with its renal denervation program in the wake of Medtronic's major setback, winning CE marking for its Renlane renal denervation system, which doctors in Europe are already using to treat drug-resistant hypertension.
Johnson & Johnson's Ethicon division won big in an ongoing suit regarding its vaginal mesh implants: After one week of testimony, a federal district judge in Charleston, WV, ruled that the company's pelvic mesh product did not cause injury.
At issue: Decision's Shasta GenStrip, a disposable glucose test strip that is designed to work with J&J's LifeScan Ultra glucose testing meters.
Looks like the FDA has taken an advisory committee's Xarelto concerns to heart. Following up on an overwhelming "no" vote from last month, the agency Friday issued Johnson & Johnson's Janssen unit complete response letters regarding use of the anticoagulant in ACS patients.